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ABSTRACT 
 
Background: Leprosy, a chronic infectious disease presents a broad clinical spectrum 
that is correlated with the immunological response of the patient, mainly related to 
Th1/Th2 cells. IL-10 is a major cytokine produced by Th2 cells inhibits 
imunostimulatory cytokine produced by Th1 cells. Suppressive effects of IL-10 on 
monocytes and cytokine synthesis by Th1 cells presumably because IL-10 has a 
general suppressive effect on immune function. Nigella sativa has a potent 
potentiating effect on cellular immunity through suppression of Th2 cells and IL-10, 
resulting in potentiation of Th1 cells.  
Method: The study design is a randomized pretest and posttest controlled design 
involving 40 subjects of Multibassiler leprosy patients. Serum levels of IL-10 were 
measured by ELISA.  
Result: The mean decrease in serum levels of IL-10 (IL-10 delta) in the treatment 
group (average fell 3.12 pg/ml) is greater than the control group (average rose 0.21 
pg/ml), where the difference is statistically significant (p = 0.029). Nigella sativa 
giving significant correlation with a decrease in IL-10 compared to the control group 
(p=0.044, OR: 10.23).  
Conclusion: Supplementation of Nigella sativa 1000 mg three times daily for 2 
months in patients with MB leprosy can reduce levels of IL-10, thus increasing the 
cellular immune response in patients with MB leprosy.  
Keywords: MB Leprosy, Nigella sativa, IL-10. 
 
INTRODUCTION 
 Leprosy is a spectrum of clinical manifestations 
associated with immune response to pathogens, 
leprosy provide exceptional knowledge in immune 
regulation in humans. On one side of the spectrum, 
patients with tuberculoid leprosy illustrates the 
resistance response that limits the growth of 
pathogens. At the end of the spectrum, there are 
patients with lepromatous leprosy excessive 
vulnerability to infection with M. leprae. This paradox 
can be explained well to the pattern of cytokines in 
lesions. Th1 cytokines, particularly IL-2 and IFN-γ, 
more strongly expressed in tuberculoid lesions. In 
contrast, Th2 cytokines, such as IL-4, IL-5 and IL-10, 
in lesions typical lepromatous.
1-3
 
One of the most important cytokine produced by Th2 
is IL-10, that inhibits cytokine synthesis produced by 
Th1 cells. Suppressive effect of IL-10 in monocytes 
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and cytokine synthesis by Th1 cells presumably 
because IL-10 has a general suppressive effect on 
immune function.
3,4  
 Some research suggests that some of the content of 
Nigella sativa has a potent potentiating effect on 
cellular immunity through potentiation of Th1 and 
Th2 cell suppression, while some others have a 
content of suppressor effects on B cell-mediated 
immunity (humoral).
5,6
 Because IL-10 is a Th2 
cytokine which has downregulation effect on Th1 cell 
and potentiating effect on B cells, IL-10 are not 
directly affected by the administration of Nigella 
sativa. Previous studies also mentioned that giving 
Nigella Sativa for 30 days would increase the levels of 
IL-4 and IFN-γ, in contrast, decreased levels of IL-10. 
Explained that the mechanisms that act is 
imunomodulatorik effect on the balance of Th1 and 
Th2 cells. Th1 type cells that secrete IL-2, IFN-γ and 
TNF-α, whereas Th2 cells secrete IL-4, IL-5 and IL-
10.
5-7
. 
 
MATERIALS AND METHODS 
 This research is true experimental design with 
randomized clinical pre and posttest control design, 
where researchers provide treatment for the provision 
of Nigella sativa 1000 mg three times daily for 2 
months on the type of MB leprosy patients were 
treated with Multidrug Therapy World Health 
Organization (MDT-WHO). Research began soon after 
the ethical clearance issued by the ethics committee 
University of Diponegoro.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
We collected leprosy patient at Donorojo Hospital 
Jepara, Jawa Tengah from August until November 
2015. Before start of the study, the research subjects 
are given information and explanations in detail about 
what will be done during research. Subjects who are 
willing to participate in the study were asked to sign a 
consent form that has been provided. Blood samples 
were taken from the mediana cubiti vein as many as 3 
cc pretreatment, and post treatment (after 2 months) 
we take blood samples again as many as 3 cc.  The 
tools is ELISA Quantikinine kit produce from 
Minneapolis, MN 55413 USA for human IL-10). 
ELISA Quantikinine kit for human IL-10 is an 
examination for the human IL-10 in serum, plasma, 
cell culture, supernatans and urine. Researcher use 
blood serum in this study. The examination using 
antibodies specific for human IL-10 at a wavelength of 
450 nm. Selection of this design is aimed to look at the 
differences in the dependent variable start of the study, 
differences in the dependent variable end of the study, 
the difference between the dependent variable and the 
beginning of the last study, the difference between a 
dependent variable of control (giving placebo, contain 
saccharum lactis that packed in capsules as same as 
Nigella sativa) and treatment groups (giving seed 
extract of Nigella sativa packed in capsules), and the 
difference of delta on dependent variable. With 
randomization technique, researchers can allocate the 
sample into two groups based on predetermined 
criterion then followed forward. Randomization 
techniques aimed at creating same characteristics of 2 
group in the study.  
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 Then, this design also allows the researchers 
conducted a double-blind, where the researcher nor the 
respondent does not know the status of the respondent 
if included in the intervention or non-intervention 
group. The strength of this design can minimize 
confounding factors that can lead to bias in the results. 
 
RESULT 
 This study managed 40 subjects who were 
diagnosed as leprosy MB type, consisting of 20 
patients with leprosy MB type treated with MDT-
WHO and Nigella sativa as supplement 3000 mg/day 
and 20 patients with leprosy MB type treated with 
MDT-WHO alone. Blood samples were taken 
pretreatment and 2 months post treatment in both 
groups. The sample analyzed and titer determination of 
the cytokine IL- 10 using ELISA technique. In the 
treatment group (Nigella sativa) majority sex is male 
(70 %), with a mean age of 36 years old, the majority 
has been graduated to primary school (55 %), a normal 
BMI (50 %), the majority have a family history 
leprosy 90 %. While in the control group (placebo) 
majority sex is male (75 %), with a mean age of 45 
years old, the majority has been graduated to primary 
school (60 %), a normal BMI (60 %), the majority 
have a family history of leprosy 85 %. (Table 1).  
 
Table 2. Correlation between Age with Serum  
Level of  IL-10 
 
  
Changes in Levels  
of Serum IL-10 
Age Correlation 
Coefficient 
-0,262 
  p 0,103
a 
  N 40 
    Korelasi  
   Spearman 
 
 From Table 1 shows that the mean age between 
the two different groups, so it needs to be further 
analyzed whether the variable age is also associated 
with changes in serum levels of IL-10. 
 From table 2 above can be seen that age is 
negatively correlated with changes in serum levels of 
IL-10, which means that when you get older the levels 
of serum IL-10 will be increased so that the changes 
fewer. However, this correlation was not statistically 
significant (p=0,103).  
 The average levels of pretreatment IL-10 in 
Nigella sativa group was 5.73 ± 2.57 pg/ml with a 
median of 5.24 (2.84 to 13.61) pg/ml and in the control 
group (by placebo), the average was 5.35 ± 1.94 pg/ml 
with a median of 5.24 (2.84 to 10.10) pg/ml, was not 
significantly different (p = 0.709) between two groups 
(Table 3). . 
 
Table 3. The Average Levels of Pre and Post 
Treatment IL-10 
Note: Wilcoxon, p < 0.05 is significant 
 
 The mean levels of serum IL-10 before treatment 
and after giving Nigella sativa was significantly 
different (p < 0.0001), where the average before 
treatment was 5.73 pg/ml greater than after treatment 
3.62 pg/ml. While in the control group before 
treatment, mean was 5.35 pg/ml less than after 
treatment was 5.56 pg/ml, where this difference was 
not statistically significant (p=0.709). The mean 
reduction in serum levels of IL - 10 in Nigella sativa 
group (average fell 3.12 pg/ml) is greater than the 
control group (average rose 0.21 pg/ml), where the 
difference was statistically significant (p=0.029). 
(Table 4). 
 
Table 4. The Average Difference of Pre and Post 
Treatment IL-10 in Control and Nigella Sativa Group 
 
Note: Mann Whitney, p < 0.05 is significant 
 
 
 Statistical analysis obtain significant correlation 
giving  Nigella sativa with a decrease in IL-10 in which  
the treatment group had a decreased likelihood 10 times 
greater than the control group (p=0.044, OR: 10.23). 
(Table 5) 
 
 
 
 
 
Group 
 
N 
Mean±SD 
(pg/ml) 
Median 
Min-
Max 
p 
NigellaSativa Pre-
treatment 
IL-10  
20 5.73±2.57 5.24 
2.84-
13.61 
<0.0001 
 Post-
treatment 
IL10 
20 2.61±2.20 1.96 
0.45-
10.10 
 
Control Pre-
treatment 
IL-10  
20 5.35±1.94 5.24 
2.84-
10.10 
0.709 
 Post-
treatment 
IL10 
20 5.56±4.70 3.77 
0.45-
14.83 
 
 
N Mean±SD 
Average 
difference 
Median Min-Max p 
Nigella 
Sativa 
20 3.12±2.22 
3.34 
2.96 -1.98-7.26 0.029a 
Control 
20 
-
0.21±4.94 
 
1.33 -11.06-5.20  
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Note: Chi square 
 
DISCUSSION 
 The study characteristics includes gender, age, level 
of education, BMI, and family history, only variables of 
age shows significant differences between the two 
groups. However, after further testing, the age variable 
is found not to contribute to reduced levels of IL-10 . So 
it can be said this study had good internal validity. This 
study has been controlled using study methodology 
design through randomization, restriction through 
inclusion and exclusion criteria, and data analysis 
process, so it was assumed to be distributed evenly in 
each. 
 This study prove that the administration of Nigella 
sativa 1000 mg three times daily for 2 months in 
patients with leprosy MB type can reduce levels of IL-
10, the mean serum levels of IL-10 early and late in 
treatment group was statistically significant (p < 
0.0001), where the average before treatment of 5.73 
pg/ml greater than after treatment of 3.62 pg/ml. The 
mean decrease in serum levels of IL-10 (IL-10 delta) in 
the treatment group (average fell 3.12 pg / ml) is greater 
than the control group (average rose 0.21 pg/ ml), where 
the difference is statistically significant (p = 0.029). The 
treatment group had a decreased likelihood 10 times 
greater than the control group (p = 0.044, OR : 10.23). 
 IL-10 is a Th2 cytokine which has the effect of 
down regulation of the Th1 cell response. Nigella sativa 
supplementation would decrease the production of IL-
10 by Th2. So that is expected to increase cellular 
immunity in patients with leprosy who receive MDT 
treatment that will ultimately improve the effectiveness 
of treatment. 
Several study had noted that the administration of 
Nigella Sativa would increase the levels of IFN-γ, in 
contrast, decreased levels of IL-10.
5-7
 Indicate that 
nigella sativa has inhibitory effects on Th2 cells and its 
cytokine as well as the effect of stimulation of the Th1 
and its cytokine. 
 Explained that the mechanisms that act is 
immunomodulatory effect on the balance of Th1 and 
Th2 cells. Th1 type cells that secrete IL-2, IFN-γ and 
TNF-α, whereas Th2 cells secrete IL-4 , IL-5 and IL-
10. The balance between Th1 and Th2 cytokines play 
an important role to determine the direction of the  
 
 
inflammatory response towards a cellular response 
form or humoral.
8-11
 
 Nigella sativa extract at a dose of 1000 mg three 
times daily can still be applied. Because humans still 
can tolerate Nigella sativa powder 2 g/day for 28 days. 
Nigella sativa in humans did not show toxic to liver 
cells, so that Nigella sativa is safe for consumption.
12,13 
 
RESEARCH LIMITATIONS 
 Limitations of this study is Nigella Sativa only as a 
supplement for the treatment of leprosy MB type with a 
dose of 1000 mg three times daily, could not be 
concluded as leprosy MB type of new drugs. This 
research has not been able to do the initial assessment of 
the relationship between the administration of Nigella 
Sativa with clinical improvement, because there are no 
parameters for clinical improvement of leprosy. 
 
CONCLUSION 
 Supplementation of Nigella sativa 1000 mg three 
times daily for 2 months in patients with leprosy MB 
type who receive MDT-WHO treatment can reduce 
levels of IL-10.  
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